Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer.
Rainville’s role includes leading the growth of Milpitas, California–based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings.
Bigfoot Unity aims to simplify CGMs and the data they produce to tell people how much insulin to take at a given point in time. It’s comprised of a smart insulin pen cap, which takes data from a CGM and informs the patient of exactly how much insulin they need.
The company has partnered with Abbott and the FreeStyle Libre 2 CGM sensor that integrates into its system, with the pen caps “talking” to the FreeStyle Libre as part of the all-encompassing design of Bigfoot Unity.
Rainville joins the company having previously served as VP and GM of global type 2 markets at Insulet. He led Insulet’s Omnipod type 2 franchise and helped expand access to insulin pumps for people with diabetes.
Before Insulet, Rainville held a number of roles across 13 years at Eli Lilly. Among those positions included leadership spots in sales, training and development, marketing, operations and market access. He contributed to the successful launch of nine diabetes products globally at Eli Lilly, according to a news release.
“Hiring a chief commercial officer is a crucial step for our business as we expand access to our Bigfoot Unity system and further develop our pipeline,” Bigfoot Biomedical CEO Jeffrey Brewer said in the release. “Matt has a proven track record developing effective commercial and market access strategies that have driven adoption of technologies for people with diabetes. His experience will serve us well as we continue to grow our presence in the commercial marketplace. We are thrilled to welcome Matt to the Bigfoot leadership team and are eager to harness his passion for improving care for people with diabetes.”
Rainville represents the latest personnel addition as Bigfoot expands its leadership team, with the company hiring a trio of executives with experience in the diabetes and healthcare sectors in December 2021.
“I’m honored to accept this role at a watershed moment for Bigfoot, as we build momentum and work to transform the management of multiple daily injections (MDI) of insulin,” Rainville said. “We have a differentiated product, a skilled team and a community of patients who need solutions for insulin management. My focus is on expanding access to these solutions for people on MDI therapy.”